MabireMHegdePHammouteneAWanJCarCSayeghRAet al
What to expect after first semaglutide injection is a common concern for patients beginning this GLP-1 medication for type 2 diabetes or weight management
Its main role is to turn fat into energy, which is efficient for brain, heart, and whole-body health
Analysts projected in 2024 that GLP-1 therapies would displace PD-1 inhibitors at the top of global drug sales rankings
Lab Invest 99:749763 Zidan A, Hedya SE, Elfeky DM, Abdin AA (2018) The possible anti-apoptotic and antioxidant effects of acetyl l-carnitine as an add-on therapy on a relapsing-remitting model of experimental autoimmune encephalomyelitis in rats

GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight
